Literature DB >> 8045974

The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys.

G Marin1, H M Domené, K M Barnes, B J Blackwell, F G Cassorla, G B Cutler.   

Abstract

To determine the effects of puberty and estrogen priming on the GH response to standardized treadmill exercise and arginine-insulin in normal boys and girls, we performed tests in 84 normal children (41 girls and 43 boys) representing all stages of puberty. A subset of the prepubertal children received the tests twice, with or without the administration of ethinyl estradiol (40 micrograms/m2 daily) for 2 days before the tests. The peak GH response to the three tests increased significantly with pubertal stage (r = 0.57; P < 0.0001), but did not differ between boys and girls at the same stage. With advancing puberty, the percentage of normal children who failed to attain a GH level greater than 7 micrograms/L during any of the three tests declined from 61% at pubertal stage 1 to 44% at stage 2, 11% at stage 3, and 0% at stages 4 and 5. Administration of estrogen to the prepubertal subjects raised the normal range for the peak GH response to the three tests from 1.9-20.3 to 7.2-40.5 micrograms/L. We conclude that both puberty and estrogen administration significantly increase the peak GH response to exercise, arginine, or insulin in normal subjects. Moreover, the conventional criterion that the peak GH response to three stimulation tests should exceed 7 micrograms/L was applicable in our study only to subjects who had attained pubertal stage 4 or 5 or who had received estrogen administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045974     DOI: 10.1210/jcem.79.2.8045974

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

1.  More guidance on growth hormone deficiency.

Authors:  R Ayling
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

Review 2.  An assessment of growth hormone provocation tests.

Authors:  P C Hindmarsh; P G Swift
Journal:  Arch Dis Child       Date:  1995-04       Impact factor: 3.791

Review 3.  Body size regulation and insulin-like growth factor signaling.

Authors:  Seogang Hyun
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

Review 4.  Genetic evaluation of short stature.

Authors:  Andrew Dauber; Ron G Rosenfeld; Joel N Hirschhorn
Journal:  J Clin Endocrinol Metab       Date:  2014-06-10       Impact factor: 5.958

Review 5.  Physiological issues surrounding the performance of adolescent athletes.

Authors:  G Naughton; N J Farpour-Lambert; J Carlson; M Bradney; E Van Praagh
Journal:  Sports Med       Date:  2000-11       Impact factor: 11.136

Review 6.  Clinical practice. Short stature in childhood--challenges and choices.

Authors:  David B Allen; Leona Cuttler
Journal:  N Engl J Med       Date:  2013-03-28       Impact factor: 91.245

7.  Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time" by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625-38].

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-08

8.  Short procedure of GHRH plus arginine test in clinical practice.

Authors:  G Aimaretti; S Bellone; C Baffoni; G Cornel; C Origlia; L Di Vito; S Rovere; E Arvat; F Camanni; E Ghigo
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

9.  Idiopathic short stature: conundrums of definition and treatment.

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2009-03-12

10.  Diagnosis of growth hormone (GH) deficiency: comparison of pituitary stalk interruption syndrome and transient GH deficiency.

Authors:  Murielle Louvel; Mariana Marcu; Christine Trivin; Jean-Claude Souberbielle; Raja Brauner
Journal:  BMC Pediatr       Date:  2009-05-06       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.